DrugPatentWatch Database Preview
DUAKLIR PRESSAIR Drug Profile
When do Duaklir Pressair patents expire, and when can generic versions of Duaklir Pressair launch?
Duaklir Pressair is a drug marketed by Circassia and is included in one NDA. There are ten patents protecting this drug.
This drug has one hundred and thirty-one patent family members in forty-three countries.
The generic ingredient in DUAKLIR PRESSAIR is aclidinium bromide; formoterol fumarate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the aclidinium bromide; formoterol fumarate profile page.
Summary for DUAKLIR PRESSAIR
| International Patents: | 131 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | DUAKLIR PRESSAIR at DailyMed |
Generic Entry Opportunity Date for DUAKLIR PRESSAIR
Generic Entry Date for DUAKLIR PRESSAIR*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER, METERED;INHALATION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for DUAKLIR PRESSAIR
| Drug Class | Anticholinergic beta2-Adrenergic Agonist |
| Mechanism of Action | Cholinergic Antagonists Adrenergic beta2-Agonists |
US Patents and Regulatory Information for DUAKLIR PRESSAIR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Circassia | DUAKLIR PRESSAIR | aclidinium bromide; formoterol fumarate | POWDER, METERED;INHALATION | 210595-001 | Mar 29, 2019 | RX | No | No | Start Trial | Start Trial | Y | Start Trial | |||
| Circassia | DUAKLIR PRESSAIR | aclidinium bromide; formoterol fumarate | POWDER, METERED;INHALATION | 210595-001 | Mar 29, 2019 | RX | No | No | Start Trial | Start Trial | Y | Start Trial | |||
| Circassia | DUAKLIR PRESSAIR | aclidinium bromide; formoterol fumarate | POWDER, METERED;INHALATION | 210595-001 | Mar 29, 2019 | RX | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for DUAKLIR PRESSAIR
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 1616592 | Start Trial |
| Brazil | 0012434 | Start Trial |
| Japan | 4030040 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for DUAKLIR PRESSAIR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1200431 | 421 | Finland | Start Trial | |
| 1200431 | 2013/002 | Ireland | Start Trial | PRODUCT NAME: ACLIDINIUM SALT WITH A PHARMACEUTICALLY ACCEPTABLE ANION OF A MONO OR POLYVALENT ACID ESPECIALLY AS ACLIDINIUM BROMIDE; NAT REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720; FIRST REGISTRATION NO/DATE: EU/1/12/781/001-003 20/07/2012 EUROPEAN UNION EU/1/12/778/001-003 20/07/2012 EUROPEAN UNION EU/1/12/781/001-003 20120720 |
| 1200431 | C300573 | Netherlands | Start Trial | PRODUCT NAME: ACLIDINIUMZOUT MET EEN FARMACEUTISCH AANVAARDBAAR ANION VAN EEN EEN- OF MEERWAARDIG ZUUR, IN HET BIJZONDER ACLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/12/778/001-003EU/1/12/781/001-003 2012200720 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
